.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01F_MacrolidesLincosamidesAndStreptogramins.J01FA15_Telithromycin.Telithromycin

Information

Telithromycin is a ketolide antibiotic, structurally related to macrolides, used to treat community-acquired pneumonia and other respiratory tract infections caused by susceptible bacteria. It is no longer widely approved due to safety concerns, particularly hepatotoxicity.

Pharmacokinetics

Reported pharmacokinetics in healthy adult volunteers after oral administration.

References

1. Shi, J, et al., & Bhargava, VO (2005). Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clinical pharmacokinetics 44(9) 915–934. DOI:10.2165/00003088-200544090-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16122280

2. Cantalloube, C, et al., & Montay, G (2003). Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. International journal of antimicrobial agents 22(2) 112–121. DOI:10.1016/s0924-8579(03)00128-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12927950

3. Zhanel, GG, et al., & Karlowsky, JA (2016). Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs 76(18) 1737–1757. DOI:10.1007/s40265-016-0667-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/27909995

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)